CA3177913A1 - Methods of treating covid-19 using bardoxolone methyl or analogs thereof - Google Patents

Methods of treating covid-19 using bardoxolone methyl or analogs thereof Download PDF

Info

Publication number
CA3177913A1
CA3177913A1 CA3177913A CA3177913A CA3177913A1 CA 3177913 A1 CA3177913 A1 CA 3177913A1 CA 3177913 A CA3177913 A CA 3177913A CA 3177913 A CA3177913 A CA 3177913A CA 3177913 A1 CA3177913 A1 CA 3177913A1
Authority
CA
Canada
Prior art keywords
patient
compound
groups
alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3177913A
Other languages
English (en)
French (fr)
Inventor
Deborah FERGUSON
W. Christian WIGLEY
Colin Meyer
J. Warren Huff
Robert M. Kral Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reata Pharmaceuticals Holdings LLC
Original Assignee
Reata Pharmaceuticals Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Holdings LLC filed Critical Reata Pharmaceuticals Holdings LLC
Publication of CA3177913A1 publication Critical patent/CA3177913A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3177913A 2020-05-09 2021-05-07 Methods of treating covid-19 using bardoxolone methyl or analogs thereof Pending CA3177913A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063022479P 2020-05-09 2020-05-09
US63/022,479 2020-05-09
US202063053056P 2020-07-17 2020-07-17
US63/053,056 2020-07-17
PCT/US2021/031282 WO2021231208A1 (en) 2020-05-09 2021-05-07 Methods of treating covid-19 using bardoxolone methyl or analogs thereof

Publications (1)

Publication Number Publication Date
CA3177913A1 true CA3177913A1 (en) 2021-11-18

Family

ID=76197607

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3177913A Pending CA3177913A1 (en) 2020-05-09 2021-05-07 Methods of treating covid-19 using bardoxolone methyl or analogs thereof

Country Status (11)

Country Link
US (1) US20230255982A1 (enExample)
EP (1) EP4146226A1 (enExample)
JP (1) JP2023526567A (enExample)
KR (1) KR20230022164A (enExample)
CN (1) CN115803059B (enExample)
AU (1) AU2021273460A1 (enExample)
BR (1) BR112022022599A2 (enExample)
CA (1) CA3177913A1 (enExample)
IL (1) IL298008A (enExample)
MX (1) MX2022014034A (enExample)
WO (1) WO2021231208A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL285832B2 (en) * 2013-08-23 2024-01-01 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
CA3240963A1 (en) * 2021-12-23 2023-06-29 Steven Laplante Drug combinations for inhibiting coronavirus replication
WO2023170187A1 (en) * 2022-03-09 2023-09-14 Technische Universität München INHIBITION OF INTRACELLULAR PATHOGEN UPTAKE BY INHIBITORS OF THE IKK-α/NIK COMPLEX
CN116509874A (zh) * 2023-02-01 2023-08-01 潍坊医学院附属医院 甲基巴多索隆在制备改善病毒性心肌炎或病毒性心肌损伤的药物中的用途
CN118903154B (zh) * 2024-08-22 2025-11-11 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 化合物CDDO-Im用于预防或治疗口蹄疫的新用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
GB9212302D0 (en) 1992-06-10 1992-07-22 Applied Research Systems Method for improving measurement precision in evanescent wave optical biosensor assays
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
DK1465615T3 (da) 2002-01-15 2012-11-12 Dartmouth College Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
EP2094651A1 (en) 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
JP5570415B2 (ja) 2007-05-08 2014-08-13 アボット・ラボラトリーズ 他のペプチド型に対する交差反応性の低いヒトｂ型ナトリウム利尿ペプチドアッセイ
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
KR100905466B1 (ko) 2007-10-08 2009-07-02 한국과학기술원 차세대 셀룰라 통신시스템에서의 중계 통신방법
ME03529B (me) 2008-01-11 2020-04-20 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
RS58392B1 (sr) 2008-04-18 2019-04-30 Reata Pharmaceuticals Inc Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17
TW201006474A (en) 2008-04-18 2010-02-16 Reata Pharmaceuticals Inc Natural products including an anti-flammatory pharmacore and methods of use
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
HUE033288T2 (en) 2008-04-18 2017-11-28 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: C-17 homologated oleic acid derivatives
SG173601A1 (en) 2009-02-13 2011-09-29 Reata Pharmaceuticals Inc Delayed release, oral dosage compositions that contain amorphous cddo-me
AU2011240690C1 (en) * 2010-04-12 2014-11-06 Reata Pharmaceuticals Holdings, LLC Method of treating obesity using antioxidant inflammation modulators
CN102875634B (zh) 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
CN102887936A (zh) 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
IL285832B2 (en) * 2013-08-23 2024-01-01 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
BR112019009256A2 (pt) * 2016-11-08 2019-07-16 Reata Pharmaceuticals, Inc. métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
WO2019014412A1 (en) 2017-07-13 2019-01-17 Pliva Hrvatska D.O.O. NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE
WO2021202547A1 (en) * 2020-04-01 2021-10-07 Triterpenoid Therapeutics, Inc. Methods and compositions for treating and preventing viral infection
WO2021202245A1 (en) * 2020-04-02 2021-10-07 Egaceutical Corporation Viral treatment regimens

Also Published As

Publication number Publication date
CN115803059B (zh) 2026-05-01
WO2021231208A1 (en) 2021-11-18
EP4146226A1 (en) 2023-03-15
CN115803059A (zh) 2023-03-14
IL298008A (en) 2023-01-01
MX2022014034A (es) 2023-01-11
JP2023526567A (ja) 2023-06-21
US20230255982A1 (en) 2023-08-17
AU2021273460A1 (en) 2022-12-08
BR112022022599A2 (pt) 2023-03-21
KR20230022164A (ko) 2023-02-14

Similar Documents

Publication Publication Date Title
AU2024200693B2 (en) Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
US20230255982A1 (en) Methods of treating covid-19 using bardoxolone methyl or analogs thereof
US20240115542A1 (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
KR20190112051A (ko) 인플루엔자의 치료 방법
WO2021226637A1 (en) Method of treating a patient infected with a coronavirus with nezulcitinib
JP2023520580A (ja) コロナウイルス誘発炎症状態の処置方法
WO2022271604A1 (en) Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
KR20170034438A (ko) 통증 치료에서의 cyp2j2 길항제
US20250114369A1 (en) Compounds and methods for treatment of viral infections
JP2014521740A (ja) Ｃｙｐ４ａ阻害剤を有効成分として含有する糖尿病又は脂肪肝の予防又は治療用薬学的組成物。
US20240100025A1 (en) Materials and Methods for Treating Viral and Other Medical Conditions
HK40089696A (en) Methods of treating covid-19 using bardoxolone methyl or analogs thereof
EP4471017A1 (en) Cyclic(alkyl)(amino)alkoxy-substituted aryl-pyrone compound and use thereof
WO2026099383A1 (en) Treatment of post-acute infection syndromes such as long covid and related symptoms
CN114426537A (zh) 2-甲基-2h-四唑类化合物及医药用途
TW202210073A (zh) 一種包含安卓幸醇之組合物用於製備抑制肝癌細胞或肝癌幹細胞生長之藥物的用途
WO2022052055A1 (zh) 一种包含安卓幸醇的组合物用于制备抑制肝癌细胞或肝癌干细胞生长的药物的用途
HK40011743B (en) Methods of treating alport syndrome using bardoxolone methyl or analogs thereof

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250424

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250424

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250424

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250424

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250424

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250625

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250625

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250625

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250625

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250709

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260312

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260421

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260421

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260709